XOMA Royalty Corporation

XOMA

US98419J2069

Entertainment Production

Real-time Estimate Cboe BZX Other stock markets 15:54:08 11/02/2026 GMT			5-day change	1st Jan Change
22.92 ^USD	+0.15%		-15.01%	-13.99%

02-05	XOMA Royalty Corporation completed the acquisition of Generation Bio Co. from Atlas Venture Life Science Advisors LLC and others.	CI
01-27	Xenotherapeutics Inc completed the acquisition of Repare Therapeutics Inc. from BVF Partners L.P., Blue Owl Healthcare Opportunities, OrbiMed Advisors LLC, and others.	CI

Xoma Royalty Completes Acquisition of Lava Therapeutics

Published on 11/21/2025 at 02:59 pm GMT

MT Newswires

Latest news about XOMA Royalty Corporation

02-05	XOMA Royalty Corporation completed the acquisition of Generation Bio Co. from Atlas Venture Life Science Advisors LLC and others.	CI
01-27	Xenotherapeutics Inc completed the acquisition of Repare Therapeutics Inc. from BVF Partners L.P., Blue Owl Healthcare Opportunities, OrbiMed Advisors LLC, and others.	CI
01-15	XOMA Royalty Corporation Announces Departure of Thomas Burns as Senior Vice President, Finance, Effective January 12, 2026	CI
01-12	XOMA Royalty Appoints New CFO; Shares Fall	MT
01-12	Xoma Royalty announces CFO transition	RE
01-12	XOMA Royalty Corporation Announces CFO Changes, Effective January 12, 2026	CI
12-30	Xoma Royalty and Takeda execute strategic royalty sharing transaction and amend existing agreement for mezagitamab	RE
12-30	XOMA Royalty Amends Takeda Deal, Expects Royalties Tied to Broader Asset Portfolio	MT
12-30	XOMA Royalty Corporation Amends Its Collaboration with Takeda Through Strategic Royalty Share Transaction	CI
12-15	Xoma Royalty enters into agreement to acquire Generation Bio	RE
12-14	XOMA Royalty Corporation entered into an agreement to acquire Generation Bio Co. for $28.92 million.	CI
12-05	XOMA Royalty Completes Acquisition of Mural Oncology	MT
12-05	Xoma Royalty announces closing of transaction to acquire Mural Oncology plc	RE
12-03	XOMA Royalty Corporation completed the acquisition of Mural Oncology plc from group of shareholders.	CI
11-26	Mural Oncology Reports Final Consideration Payable on Closing of Acquisition by Xoma	MT
11-21	Xoma Royalty Completes Acquisition of Lava Therapeutics	MT
11-21	Xoma Royalty announces closing of transactions to acquire LAVA Therapeutics N.V.	RE
11-19	XOMA Royalty Corporation completed the acquisition of LAVA Therapeutics N.V..	CI
11-13	Xenotherapeutics Inc signed a definitive arrangement agreement to acquire Repare Therapeutics Inc. for $78.7 million.	CI
11-12	XOMA Royalty Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-12	Tranche Update on XOMA Royalty Corporation's Equity Buyback Plan announced on January 2, 2024.	CI
11-12	Biotech royalty aggregator XOMA reports Q3 net income of $14.1 mln	RE
24/10/25	Mural Oncology Shareholders Approve $36.2 Million Sale to XOMA Royalty Unit	MT
17/10/25	XOMA Royalty Lowers Cash Offer for Lava Therapeutics, Extends Tender Deadline	MT
17/10/25	Xoma Royalty and Lava Therapeutics announce amendment to purchase agreement	RE

Chart XOMA Royalty Corporation

Duration

Period

XOMA: Dynamic Chart

XOMA Royalty Corporation is a biotechnology royalty aggregator. The Companyâ€™s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's royalty portfolio includes OJEMDA (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, mezagitamab (TAK-079), acimtamig (AFM13), AB054, ficlatuzumab (AV-299), COM902, vosaroxin, aldoxorubicin, INCAGN02385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], CMP-001 (vidutolimod), NTM-1631, NTM-1634, NTM-1633, NTM-1632, NIR178, MK-4830, AFM24, INCAGN01949, AB101, and CFZ533 (iscalimab).

Employees

Sector

Entertainment Production

Calendar

03-04 - Q4 2025 Earnings Release (Projected)

More about the company